Product Description
The global drug-coated balloon (DCB) market was valued at $523 million in 2025. This is expected to increase over the forecast period at a CAGR of 5% to reach $735 million by 2032.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Drug-Coated Balloon (DCB) Market Trends
An emerging trend in the global DCB market is the continuous refinement of coating technologies and the expansion of DCB applications beyond coronary and peripheral interventions. Manufacturers are actively developing advanced coatings that enhance drug delivery efficiency, durability and biocompatibility, thereby improving treatment outcomes and reducing the risk of restenosis. Moreover, the utilization of DCBs is expanding into newer clinical areas, such as the treatment of small vessels, bifurcation lesions and in-stent restenosis, widening the scope of DCB applications and further contributing to their prominence as a versatile tool in interventional cardiology and peripheral vascular procedures.
Drug-Coated Balloon (DCB) Market Share Insights
- Medtronic dominated the global DCB market, driven by the PACT Admiral™ paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter with superior clinical outcomes. This led to a moderately higher market share. The U.S. Food and Drug Administration’s (FDA’s) late 2019 approval of IN.PACT AV bolstered Medtronic’s considerable share in arteriovenous (AV) access DCBs. While expanding into adjacent segments, Medtronic’s share is anticipated to decrease due to rising competition like Philips’ Stellarex® DCB. Becton Dickinson launched Lutonix® in 2014 before Medtronic’s IN.PACT™, historically leading in account numbers but now sharing an even overall market share. Medtronic’s IN.PACT Admiral™ gained FDA approval for various procedures, contributing to its growth in the market.
- Becton Dickinson (formerly C. R. Bard) led the way with the first FDA-approved DCB in the U.S., the Lutonix® 035 drug-coated balloon PTA catheter, for thigh and knee artery blockages in October 2014. Clinical excellence of Medtronic’s PACT Admiral™ resulted in greater superficial femoral artery (SFA) DCB market share. Becton Dickinson also introduced the Lutonix® 035 DCB for dysfunctional AV fistula, later challenged by IN.PACT Admiral™. Despite leading the BTK DCB race, FDA rejection tied to paclitaxel concerns slowed the progress, yet plans persist for an uptick in DCB unit sales growth. Facing competition from Philips’ Stellarex® and Boston Scientific’s Ranger, Becton Dickinson’s market share is anticipated to decline, compounded by AV access loss to Medtronic.
- Boston Scientific held the third position in the global DCB market. In November 2020, the company gained FDA approval for its Ranger™ drug-coated balloon to treat peripheral arterial disease (PAD) in the SFA and proximal popliteal artery (PPA) in 2025. This approval was grounded in findings from the pivotal RANGER II SFA trial, comparing Ranger DCB’s safety and effectiveness against standard PTA for PAD treatment in the SFA and PPA.
Drug-Coated Balloon (DCB) Market Segmentation Summary
- Drug-Coated Balloon Market – Further Segmented Into:
- Unit Analysis By Indication: SFA and AV Access.
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
